Search

Search bills, members, committees and pages...

H.R. 9743

U.S. HouseIn House Committee

Summary

H.R. 9743, the TRUTH in Coverage Act of 2026, was introduced in the House on Jul 16, 2026 by Rep. Diana Harshbarger (R) with 13 co-sponsors. It was referred to Energy And Commerce, and last saw action on Jul 16, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


Record

Text

H.R. 9743 has 13 co-sponsors.

hr9743/introduced-in-house.txt
119 HR 9743 IH: Treatment and Restoration Uniformity and Transparency in Health Coverage Act of 2026
U.S. House of Representatives
2026-07-16
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
I 119th CONGRESS 2d Session H. R. 9743 IN THE HOUSE OF REPRESENTATIVES July 16, 2026 Mrs. Harshbarger (for herself, Mr. Carter of Georgia , Mr. McGuire , Mr. Kennedy of Utah , Mr. Carter of Texas , Mr. Fuller , Mr. Van Epps , Mrs. Biggs of South Carolina , Mr. Babin , Mrs. Miller of Illinois , Mr. Stutzman , Mr. Hamadeh of Arizona , and Mr. Ciscomani ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committees on Education and Workforce , and Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL
To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to require group health plans and health insurance issuers offering group or individual health insurance coverage that provide benefits for sex-rejecting procedures to provide benefits for items and services to address the harms caused by sex-rejecting procedures and to restore healthy human form and functioning, to the greatest extent practicable.
1.
Short title
This Act may be cited as the Treatment and Restoration Uniformity and Transparency in Health Coverage Act of 2026 or the TRUTH in Coverage Act of 2026 .
2.
Requiring group health plans and health insurance issuers offering group or individual health insurance coverage that provide benefits for sex-rejecting procedures to provide benefits for items and services to address the harms of such procedures
(a)
PHSA
Part D of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg–111 et seq. ) is amended by adding at the end the following new section:
2799A–12.
Required coverage of items and services to address the harms of sex-rejecting procedures
(a)
In general
A group health plan and a health insurance issuer offering group or individual health insurance coverage shall, in the case such plan or coverage provides benefits with respect to any sex-rejecting procedure, also provide benefits for items and services furnished to an individual who has received any such procedure to address the harms of such procedure (including restorative care), regardless of whether—
(1)
such individual received benefits with respect to the sex-rejecting procedure under the individual’s plan or coverage; or
(2)
such plan or issuer provides benefits under the individual’s plan or coverage for the sex-rejecting procedure.
(b)
Application of financial requirements and treatment limitations
A group health plan and a health insurance issuer offering group or individual health insurance coverage shall ensure that, with respect to items and services for which benefits to address the harms of sex-rejecting procedures are required to be provided under such plan or coverage under subsection (a)—
(1)
the financial requirements applicable to such items and services are no more restrictive than the predominant financial requirements applied to substantially all medical and surgical benefits covered by the plan or coverage and there are no separate cost-sharing requirements that are applicable only with respect to such items and services; and
(2)
the treatment limitations applicable to such items and services are no more restrictive than the predominant treatment limitations applied to substantially all medical and surgical benefits covered by the plan or coverage and there are no separate treatment limitations that are applicable only with respect to such items and services.
(c)
Definitions
In this section:
(1)
Female
Referring to a natural person, the term female means an individual characterized by a reproductive system naturally organized to produce (at maturity, absent disruption or congenital anomaly) large gametes (ova).
(2)
Financial requirement; predominant; treatment limitation
The terms financial requirement , predominant , and treatment limitation have the meaning given such terms in clauses (i) through (iii), respectively, of section 2726(a)(3)(B), except that the term financial requirement shall include aggregate lifetime limits and annual limits.
(3)
Male
Referring to a natural person, the term male means an individual characterized by a reproductive system naturally organized to produce (at maturity, absent disruption or congenital anomaly) small gametes (sperm).
(4)
Restorative care
The term restorative care means items and services furnished to an individual who has received any sex-rejecting procedure at any point during the individual’s lifetime to address, mitigate, monitor, treat, or reverse the harms, complications, and adverse effects of such procedure, including interventions intended to restore, to the greatest extent practicable, healthy human form and functioning. Such care includes items and services furnished to address—
(A)
impaired reproductive capacity, diminished ovarian reserve, impaired spermatogenesis, or other reproductive-system injury;
(B)
endocrine dysfunction, hormonal imbalance, hypogonadism, dependence on exogenous hormones, or other disruption of healthy endocrine function;
(C)
impaired sexual function, including loss of sexual sensation, anorgasmia, erectile dysfunction, genital pain, vaginal stenosis, diminished libido, or other sexual dysfunction;
(D)
urinary dysfunction, including urinary incontinence, urinary retention, urethral complications, recurrent urinary tract infections, or other genitourinary injury;
(E)
resultant vocal cord damage, permanent voice changes, vocal dysfunction, or impaired speech;
(F)
female hirsutism, male-pattern baldness, breast atrophy, breast development, or other secondary-sex-characteristic changes caused by cross-sex hormones;
(G)
osteoporosis, osteopenia, impaired bone development, fractures, reduced bone density, or other skeletal disorders associated with puberty suppression or cross-sex hormone use;
(H)
cardiovascular disease, thromboembolic disease, hypertension, stroke, myocardial infarction, metabolic syndrome, diabetes, or other cardiovascular or metabolic complications associated with such procedures;
(I)
surgical complications, including infection, fistula formation, stenosis, tissue necrosis, chronic pain, nerve damage, graft failure, implant complications, wound complications, or the need for revision surgery;
(J)
loss, removal, alteration, or impairment of healthy reproductive organs, breasts, genital structures, or other healthy tissues;
(K)
reconstructive, regenerative, prosthetic, plastic, or other surgical interventions intended to restore healthy anatomy, appearance, or physiological function;
(L)
rehabilitation services, including speech therapy, physical therapy, occupational therapy, pelvic floor therapy, sexual health counseling, and other therapies intended to restore healthy functioning;
(M)
psychiatric or psychological conditions associated with or exacerbated by such procedures, including depression, anxiety, trauma, suicidality, grief, regret, identity distress, body-image disturbance, or dissociation;
(N)
diagnostic testing, specialist evaluations, fertility assessments, hormone monitoring, cancer screening, and long-term medical surveillance necessitated by altered anatomy or prior exposure to puberty blockers, cross-sex hormones, or sex-rejecting surgeries;
(O)
fertility services that seek to cooperate with, or restore the healthy physiology and anatomy of, the human reproductive system, without the use of methods that circumvent natural human functions, such as any treatments or procedures that involve the handling of a human egg or embryo outside the body;
(P)
breast cancer in men on estrogen and certain cancers in women on testosterone; and
(Q)
any other physical, psychological, reproductive, endocrine, neurologic, cardiovascular, musculoskeletal, or metabolic injury, impairment, complication, or condition resulting from or associated with a sex-rejecting procedure.
(5)
Sex
The term sex , when referring to an individual’s sex, means to refer to either male or female, as genetically determined at fertilization.
(6)
Sex-rejecting procedure
(A)
In general
The term sex-rejecting procedure means any medical or surgical intervention for the purpose of attempting to align an individual’s physical appearance or body with an asserted identity that differs from the individual’s sex, including—
(i)
gonadotropin-releasing hormone (GnRH) agonists or any other puberty-blocking or suppressing drugs to stop or delay normal puberty;
(ii)
testosterone, dihydrotestosterone (DHT), or other androgens, estrogen, progesterone, to an individual at doses that are supraphysiologic to what would normally be produced endogenously in a healthy individual of the same age and sex, as well as anti-androgen medications;
(iii)
castration;
(iv)
orchiectomy;
(v)
scrotoplasty;
(vi)
implantation of erection or testicular prostheses;
(vii)
vasectomy;
(viii)
hysterectomy;
(ix)
oophorectomy;
(x)
ovariectomy;
(xi)
reconstruction of the fixed part of the urethra with or without a metoidioplasty or a phalloplasty;
(xii)
metoidioplasty;
(xiii)
penectomy;
(xiv)
phalloplasty;
(xv)
vaginoplasty;
(xvi)
clitoroplasty;
(xvii)
vaginectomy;
(xviii)
vulvoplasty;
(xix)
reduction thyrochondroplasty;
(xx)
chondrolaryngoplasty;
(xxi)
mastectomy;
(xxii)
tubal ligation;
(xxiii)
sterilization;
(xxiv)
any plastic, cosmetic, or aesthetic surgery that feminizes or masculinizes the facial or other physiological features of an individual;
(xxv)
any placement of chest implants to create feminine breasts;
(xxvi)
any placement of fat or artificial implants in the gluteal region;
(xxvii)
augmentation mammoplasty;
(xxviii)
liposuction;
(xxix)
lipofilling;
(xxx)
voice surgery;
(xxxi)
hair reconstruction;
(xxxii)
pectoral implants; and
(xxxiii)
the removal of any otherwise healthy or non-diseased body part or tissue.
(B)
Exceptions
The term sex-rejecting procedure does not include the following when furnished by a health care professional with the consent of such individual or, if applicable, such individual’s parents or legal guardian:
(i)
Services to individuals born with a medically verifiable disorder of sex development, including an individual with external sex characteristics that are irresolvably ambiguous, such as an individual born with 46,XX chromosomes with virilization, an individual born with 46,XY chromosomes with undervirilization, or an individual born having both ovarian and testicular tissue.
(ii)
Services provided when a physician has otherwise diagnosed a disorder of sex development in which the physician has determined through genetic or biochemical testing that the individual does not have healthy sex chromosome structure, sex steroid hormone production, or sex steroid hormone action for a healthy individual of the same sex and age.
(iii)
The treatment of any infection, injury, disease, or disorder that has been caused by or exacerbated by the performance of sex-rejecting procedures, whether or not the sex-rejecting procedure was performed in accordance with State and Federal law and whether or not funding for the procedure is permissible under this section.
(iv)
Any procedure undertaken because the individual suffers from a physical disorder, physical injury, or physical illness (but not claimed mental distress) that would, as certified by a physician, place the individual in imminent danger of death or impairment of major bodily function, unless the procedure is performed.
(v)
Puberty suppression or blocking prescription drugs for the purpose of normalizing puberty for a minor experiencing precocious puberty.
(vi)
Male circumcision.
.
(b)
ERISA
(1)
In general
Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1185 et seq. ) is amended by adding at the end the following new section:
727.
Required coverage of items and services to address the harms of sex-rejecting procedures
(a)
In general
A group health plan and a health insurance issuer offering group health insurance coverage shall, in the case such plan or coverage provides benefits with respect to any sex-rejecting procedure, also provide benefits for items and services furnished to an individual who has received any such procedure to address the harms of such procedure (including restorative care), regardless of whether—
(1)
such individual received benefits with respect to the sex-rejecting procedure under the individual’s plan or coverage; or
(2)
such plan or issuer provides benefits under the individual’s plan or coverage for the sex-rejecting procedure.
(b)
Application of financial requirements and treatment limitations
A group health plan and a health insurance issuer offering group health insurance coverage shall ensure that, with respect to items and services for which benefits to address the harms of sex-rejecting procedures are required to be provided under such plan or coverage under subsection (a)—
(1)
the financial requirements applicable to such items and services are no more restrictive than the predominant financial requirements applied to substantially all medical and surgical benefits covered by the plan or coverage and there are no separate cost-sharing requirements that are applicable only with respect to such items and services; and
(2)
the treatment limitations applicable to such items and services are no more restrictive than the predominant treatment limitations applied to substantially all medical and surgical benefits covered by the plan or coverage and there are no separate treatment limitations that are applicable only with respect to such items and services.
(c)
Definitions
In this section:
(1)
Female
Referring to a natural person, the term female means an individual characterized by a reproductive system naturally organized to produce (at maturity, absent disruption or congenital anomaly) large gametes (ova).
(2)
Financial requirement; predominant; treatment limitation
The terms financial requirement , predominant , and treatment limitation have the meaning given such terms in clauses (i) through (iii), respectively, of section 712(a)(3)(B), except that the term financial requirement shall include aggregate lifetime limits and annual limits.
(3)
Male
Referring to a natural person, the term male means an individual characterized by a reproductive system naturally organized to produce (at maturity, absent disruption or congenital anomaly) small gametes (sperm).
(4)
Restorative care
The term restorative care means items and services furnished to an individual who has received any sex-rejecting procedure at any point during the individual’s lifetime to address, mitigate, monitor, treat, or reverse the harms, complications, and adverse effects of such procedure, including interventions intended to restore, to the greatest extent practicable, healthy human form and functioning. Such care includes items and services furnished to address—
(A)
impaired reproductive capacity, diminished ovarian reserve, impaired spermatogenesis, or other reproductive-system injury;
(B)
endocrine dysfunction, hormonal imbalance, hypogonadism, dependence on exogenous hormones, or other disruption of healthy endocrine function;
(C)
impaired sexual function, including loss of sexual sensation, anorgasmia, erectile dysfunction, genital pain, vaginal stenosis, diminished libido, or other sexual dysfunction;
(D)
urinary dysfunction, including urinary incontinence, urinary retention, urethral complications, recurrent urinary tract infections, or other genitourinary injury;
(E)
resultant vocal cord damage, permanent voice changes, vocal dysfunction, or impaired speech;
(F)
female hirsutism, male-pattern baldness, breast atrophy, breast development, or other secondary-sex-characteristic changes caused by cross-sex hormones;
(G)
osteoporosis, osteopenia, impaired bone development, fractures, reduced bone density, or other skeletal disorders associated with puberty suppression or cross-sex hormone use;
(H)
cardiovascular disease, thromboembolic disease, hypertension, stroke, myocardial infarction, metabolic syndrome, diabetes, or other cardiovascular or metabolic complications associated with such procedures;
(I)
surgical complications, including infection, fistula formation, stenosis, tissue necrosis, chronic pain, nerve damage, graft failure, implant complications, wound complications, or the need for revision surgery;
(J)
loss, removal, alteration, or impairment of healthy reproductive organs, breasts, genital structures, or other healthy tissues;
(K)
reconstructive, regenerative, prosthetic, plastic, or other surgical interventions intended to restore healthy anatomy, appearance, or physiological function;
(L)
rehabilitation services, including speech therapy, physical therapy, occupational therapy, pelvic floor therapy, sexual health counseling, and other therapies intended to restore healthy functioning;
(M)
psychiatric or psychological conditions associated with or exacerbated by such procedures, including depression, anxiety, trauma, suicidality, grief, regret, identity distress, body-image disturbance, or dissociation;
(N)
diagnostic testing, specialist evaluations, fertility assessments, hormone monitoring, cancer screening, and long-term medical surveillance necessitated by altered anatomy or prior exposure to puberty blockers, cross-sex hormones, or sex-rejecting surgeries;
(O)
fertility services that seek to cooperate with, or restore the healthy physiology and anatomy of, the human reproductive system, without the use of methods that circumvent natural human functions, such as any treatments or procedures that involve the handling of a human egg or embryo outside the body;
(P)
breast cancer in men on estrogen and certain cancers in women on testosterone; and
(Q)
any other physical, psychological, reproductive, endocrine, neurologic, cardiovascular, musculoskeletal, or metabolic injury, impairment, complication, or condition resulting from or associated with a sex-rejecting procedure.
(5)
Sex
The term sex , when referring to an individual’s sex, means to refer to either male or female, as genetically determined at fertilization.
(6)
Sex-rejecting procedure
(A)
In general
The term sex-rejecting procedure means any medical or surgical intervention for the purpose of attempting to align an individual’s physical appearance or body with an asserted identity that differs from the individual’s sex, including—
(i)
gonadotropin-releasing hormone (GnRH) agonists or any other puberty-blocking or suppressing drugs to stop or delay normal puberty;
(ii)
testosterone, dihydrotestosterone (DHT), or other androgens, estrogen, progesterone, to an individual at doses that are supraphysiologic to what would be produced endogenously in a healthy individual of the same age and sex, as well as anti-androgen medications;
(iii)
castration;
(iv)
orchiectomy;
(v)
scrotoplasty;
(vi)
implantation of erection or testicular prostheses;
(vii)
vasectomy;
(viii)
hysterectomy;
(ix)
oophorectomy;
(x)
ovariectomy;
(xi)
reconstruction of the fixed part of the urethra with or without a metoidioplasty or a phalloplasty;
(xii)
metoidioplasty;
(xiii)
penectomy;
(xiv)
phalloplasty;
(xv)
vaginoplasty;
(xvi)
clitoroplasty;
(xvii)
vaginectomy;
(xviii)
vulvoplasty;
(xix)
reduction thyrochondroplasty;
(xx)
chondrolaryngoplasty;
(xxi)
mastectomy;
(xxii)
tubal ligation;
(xxiii)
sterilization;
(xxiv)
any plastic, cosmetic, or aesthetic surgery that feminizes or masculinizes the facial or other physiological features of an individual;
(xxv)
any placement of chest implants to create feminine breasts;
(xxvi)
any placement of fat or artificial implants in the gluteal region;
(xxvii)
augmentation mammoplasty;
(xxviii)
liposuction;
(xxix)
lipofilling;
(xxx)
voice surgery;
(xxxi)
hair reconstruction;
(xxxii)
pectoral implants; and
(xxxiii)
the removal of any otherwise healthy or non-diseased body part or tissue.
(B)
Exceptions
The term sex-rejecting procedure does not include the following when furnished by a health care professional with the consent of such individual or, if applicable, such individual’s parents or legal guardian:
(i)
Services to individuals born with a medically verifiable disorder of sex development, including an individual with external sex characteristics that are irresolvably ambiguous, such as an individual born with 46,XX chromosomes with virilization, an individual born with 46,XY chromosomes with undervirilization, or an individual born having both ovarian and testicular tissue.
(ii)
Services provided when a physician has otherwise diagnosed a disorder of sex development in which the physician has determined through genetic or biochemical testing that the individual does not have healthy sex chromosome structure, sex steroid hormone production, or sex steroid hormone action for a healthy individual of the same sex and age.
(iii)
The treatment of any infection, injury, disease, or disorder that has been caused by or exacerbated by the performance of sex-rejecting procedures, whether or not the sex-rejecting procedure was performed in accordance with State and Federal law and whether or not funding for the procedure is permissible under this section.
(iv)
Any procedure undertaken because the individual suffers from a physical disorder, physical injury, or physical illness (but not claimed mental distress) that would, as certified by a physician, place the individual in imminent danger of death or impairment of major bodily function, unless the procedure is performed.
(v)
Puberty suppression or blocking prescription drugs for the purpose of normalizing puberty for a minor experiencing precocious puberty.
(vi)
Male circumcision.
.
(2)
Clerical amendment
The table of contents in section 1 of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1001 note) is amended by inserting after the item relating to section 726 the following new item:
Sec. 727. Required coverage of items and services to address the harms of sex-rejecting procedures.
.
(c)
IRC
(1)
In general
Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:
9827.
Required coverage of items and services to address the harms of sex-rejecting procedures
(a)
In general
A group health plan shall, in the case such plan provides benefits with respect to any sex-rejecting procedure, also provide benefits for items and services furnished to an individual who has received any such procedure to address the harms of such procedure (including restorative care), regardless of whether—
(1)
such individual received benefits with respect to the sex-rejecting procedure under the individual’s plan; or
(2)
such plan provides benefits under the individual’s plan for the sex-rejecting procedure.
(b)
Application of financial requirements and treatment limitations
A group health plan shall ensure that, with respect to items and services for which benefits to address the harms of sex-rejecting procedures are required to be provided under such plan under subsection (a)—
(1)
the financial requirements applicable to such items and services are no more restrictive than the predominant financial requirements applied to substantially all medical and surgical benefits covered by the plan and there are no separate cost-sharing requirements that are applicable only with respect to such items and services; and
(2)
the treatment limitations applicable to such items and services are no more restrictive than the predominant treatment limitations applied to substantially all medical and surgical benefits covered by the plan and there are no separate treatment limitations that are applicable only with respect to such items and services.
(c)
Definitions
In this section:
(1)
Female
Referring to a natural person, the term female means an individual characterized by a reproductive system naturally organized to produce (at maturity, absent disruption or congenital anomaly) large gametes (ova).
(2)
Financial requirement; predominant; treatment limitation
The terms financial requirement , predominant , and treatment limitation have the meaning given such terms in clauses (i) through (iii), respectively, of section 9812(a)(3)(B), except that the term financial requirement shall include aggregate lifetime limits and annual limits.
(3)
Male
Referring to a natural person, the term male means an individual characterized by a reproductive system naturally organized to produce (at maturity, absent disruption or congenital anomaly) small gametes (sperm).
(4)
Restorative care
The term restorative care means items and services furnished to an individual who has received any sex-rejecting procedure at any point during the individual’s lifetime to address, mitigate, monitor, treat, or reverse the harms, complications, and adverse effects of such procedure, including interventions intended to restore, to the greatest extent practicable, healthy human form and functioning. Such care includes items and services furnished to address—
(A)
impaired reproductive capacity, diminished ovarian reserve, impaired spermatogenesis, or other reproductive-system injury;
(B)
endocrine dysfunction, hormonal imbalance, hypogonadism, dependence on exogenous hormones, or other disruption of healthy endocrine function;
(C)
impaired sexual function, including loss of sexual sensation, anorgasmia, erectile dysfunction, genital pain, vaginal stenosis, diminished libido, or other sexual dysfunction;
(D)
urinary dysfunction, including urinary incontinence, urinary retention, urethral complications, recurrent urinary tract infections, or other genitourinary injury;
(E)
resultant vocal cord damage, permanent voice changes, vocal dysfunction, or impaired speech;
(F)
female hirsutism, male-pattern baldness, breast atrophy, breast development, or other secondary-sex-characteristic changes caused by cross-sex hormones;
(G)
osteoporosis, osteopenia, impaired bone development, fractures, reduced bone density, or other skeletal disorders associated with puberty suppression or cross-sex hormone use;
(H)
cardiovascular disease, thromboembolic disease, hypertension, stroke, myocardial infarction, metabolic syndrome, diabetes, or other cardiovascular or metabolic complications associated with such procedures;
(I)
surgical complications, including infection, fistula formation, stenosis, tissue necrosis, chronic pain, nerve damage, graft failure, implant complications, wound complications, or the need for revision surgery;
(J)
loss, removal, alteration, or impairment of healthy reproductive organs, breasts, genital structures, or other healthy tissues;
(K)
reconstructive, regenerative, prosthetic, plastic, or other surgical interventions intended to restore healthy anatomy, appearance, or physiological function;
(L)
rehabilitation services, including speech therapy, physical therapy, occupational therapy, pelvic floor therapy, sexual health counseling, and other therapies intended to restore healthy functioning;
(M)
psychiatric or psychological conditions associated with or exacerbated by such procedures, including depression, anxiety, trauma, suicidality, grief, regret, identity distress, body-image disturbance, or dissociation;
(N)
diagnostic testing, specialist evaluations, fertility assessments, hormone monitoring, cancer screening, and long-term medical surveillance necessitated by altered anatomy or prior exposure to puberty blockers, cross-sex hormones, or sex-rejecting surgeries;
(O)
fertility services that seek to cooperate with, or restore the healthy physiology and anatomy of, the human reproductive system, without the use of methods that circumvent natural human functions, such as any treatments or procedures that involve the handling of a human egg or embryo outside the body;
(P)
breast cancer in men on estrogen and certain cancers in women on testosterone; and
(Q)
any other physical, psychological, reproductive, endocrine, neurologic, cardiovascular, musculoskeletal, or metabolic injury, impairment, complication, or condition resulting from or associated with a sex-rejecting procedure.
(5)
Sex
The term sex , when referring to an individual’s sex, means to refer to either male or female, as genetically determined at fertilization.
(6)
Sex-rejecting procedure
(A)
In general
The term sex-rejecting procedure means any medical or surgical intervention for the purpose of attempting to align an individual’s physical appearance or body with an asserted identity that differs from the individual’s sex, including—
(i)
gonadotropin-releasing hormone (GnRH) agonists or any other puberty-blocking or suppressing drugs to stop or delay normal puberty;
(ii)
testosterone, dihydrotestosterone (DHT), or other androgens, estrogen, progesterone, to an individual at doses that are supraphysiologic to what would normally be produced endogenously in a healthy individual of the same age and sex, as well as anti-androgen medications;
(iii)
castration;
(iv)
orchiectomy;
(v)
scrotoplasty;
(vi)
implantation of erection or testicular prostheses;
(vii)
vasectomy;
(viii)
hysterectomy;
(ix)
oophorectomy;
(x)
ovariectomy;
(xi)
reconstruction of the fixed part of the urethra with or without a metoidioplasty or a phalloplasty;
(xii)
metoidioplasty;
(xiii)
penectomy;
(xiv)
phalloplasty;
(xv)
vaginoplasty;
(xvi)
clitoroplasty;
(xvii)
vaginectomy;
(xviii)
vulvoplasty;
(xix)
reduction thyrochondroplasty;
(xx)
chondrolaryngoplasty;
(xxi)
mastectomy;
(xxii)
tubal ligation;
(xxiii)
sterilization;
(xxiv)
any plastic, cosmetic, or aesthetic surgery that feminizes or masculinizes the facial or other physiological features of an individual;
(xxv)
any placement of chest implants to create feminine breasts;
(xxvi)
any placement of fat or artificial implants in the gluteal region;
(xxvii)
augmentation mammoplasty;
(xxviii)
liposuction;
(xxix)
lipofilling;
(xxx)
voice surgery;
(xxxi)
hair reconstruction;
(xxxii)
pectoral implants; and
(xxxiii)
the removal of any otherwise healthy or non-diseased body part or tissue.
(B)
Exceptions
The term sex-rejecting procedure does not include the following when furnished by a health care professional with the consent of such individual or, if applicable, such individual’s parents or legal guardian:
(i)
Services to individuals born with a medically verifiable disorder of sex development, including an individual with external sex characteristics that are irresolvably ambiguous, such as an individual born with 46,XX chromosomes with virilization, an individual born with 46,XY chromosomes with undervirilization, or an individual born having both ovarian and testicular tissue.
(ii)
Services provided when a physician has otherwise diagnosed a disorder of sex development in which the physician has determined through genetic or biochemical testing that the individual does not have healthy sex chromosome structure, sex steroid hormone production, or sex steroid hormone action for a healthy individual of the same sex and age.
(iii)
The treatment of any infection, injury, disease, or disorder that has been caused by or exacerbated by the performance of sex-rejecting procedures, whether or not the sex-rejecting procedure was performed in accordance with State and Federal law and whether or not funding for the procedure is permissible under this section.
(iv)
Any procedure undertaken because the individual suffers from a physical disorder, physical injury, or physical illness (but not claimed mental distress) that would, as certified by a physician, place the individual in imminent danger of death or impairment of major bodily function, unless the procedure is performed.
(v)
Puberty suppression or blocking prescription drugs for the purpose of normalizing puberty for a minor experiencing precocious puberty.
(vi)
Male circumcision.
.
(2)
Clerical amendment
The table of sections for subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:
Sec. 9827. Required coverage of items and services to address the harms of sex-rejecting procedures.
.
(d)
Effective date
The amendments made by this section shall apply with respect to plan years beginning on or after January 1, 2027.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2026-07-16
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to require group health plans and health insurance issuers offering group or individual health insurance coverage that provide benefits for sex-rejecting procedures to provide benefits for items and services to address the harms caused by sex-rejecting procedures and to restore healthy human form and functioning, to the greatest extent practicable.

Sponsors

Rep. Diana Harshbarger (R) sponsors H.R. 9743, and 13 members have co-sponsored it, 12 of them from the day it was introduced.

Committees

H.R. 9743 went before 3 committees: Ways and Means, Education and Workforce and Energy and Commerce.

Ways and Means
Ways and Means
Referred To · Jul 16, 2026 · 1,160 Bills
Education and Workforce
Education and Workforce
Referred To · Jul 16, 2026 · 824 Bills
Energy and Commerce
Energy and Commerce
Referred To · Jul 16, 2026 · 1,636 Bills

Actions

H.R. 9743 has taken 2 actions since Jul 16, 2026.

ChamberAction
Jul 16, 2026
House
Introduced in House
Jul 16, 2026
House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee

Votes

H.R. 9743 has not gone to a roll call.

1 bill is related to H.R. 9743, as Identical bill.

Titles

H.R. 9743 goes by 4 titles, 2 of them short titles.

  • TRUTH in Coverage Act of 2026 — Display Title
  • TRUTH in Coverage Act of 2026 — Short Title(s) as Introduced
  • Treatment and Restoration Uniformity and Transparency in Health Coverage Act of 2026 — Short Title(s) as Introduced
  • To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to require group health plans and health insurance issuers offering group or individual health insurance coverage that provide benefits for sex-rejecting procedures to provide benefits for items and services to address the harms caused by sex-rejecting procedures and to restore healthy human form and functioning, to the greatest extent practicable. — Official Title as Introduced

Classification

The Congressional Research Service files H.R. 9743 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 9743’s is Health.

hr9743/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 9743, as entered in the Congressional Record.

[Congressional Record Volume 172, Number 116 (Thursday, July 16, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mrs. HARSHBARGER:H.R. 9743.Congress has the power to enact this legislation pursuantto the following:Article I; Section 8 of the United States Constitution[Page H4624]

Source: congress.gov · legiscan.com